EASL-EASD-EASO. Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. https://doi.org/10.1016/j.jhep.2024.04.031.

Article  CAS  Google Scholar 

Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057–82. https://doi.org/10.2337/dci24-0094.

Article  PubMed  CAS  Google Scholar 

Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, et al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025;169(5):1017–e322. https://doi.org/10.1053/j.gastro.2025.02.044.

Article  PubMed  CAS  Google Scholar 

Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65. https://doi.org/10.1002/hep.29085.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32–50. https://doi.org/10.3350/cmh.2024.0431.

Article  PubMed  Google Scholar 

Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471–8. https://doi.org/10.1016/j.jhep.2022.11.010.

Article  PubMed  CAS  Google Scholar 

Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999–e20108. https://doi.org/10.1016/j.cgh.2024.03.006.

Article  PubMed  Google Scholar 

Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611–e2512. https://doi.org/10.1053/j.gastro.2020.01.043.

Article  PubMed  CAS  Google Scholar 

Huang DQ, Wilson LA, Behling C, Kleiner DE, Kowdley KV, Dasarathy S, et al. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. Gastroenterology. 2023;165(2):463–e725. https://doi.org/10.1053/j.gastro.2023.04.025.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Simon TG, Roelstraete B, Sharma R, Khalili H, Hagström H, Ludvigsson JF. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatology. 2021;74(5):2410–23. https://doi.org/10.1002/hep.31845.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702. https://doi.org/10.1136/gutjnl-2023-330595.

Article  PubMed  CAS  Google Scholar 

Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867–75. https://doi.org/10.1136/gutjnl-2021-325724.

Article  PubMed  Google Scholar 

Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–13. https://doi.org/10.1016/s2468-1253(21)00308-3.

Article  PubMed  Google Scholar 

Pharmacologic Approaches to Glycemic Treatment. Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181–206. https://doi.org/10.2337/dc25-S009.

Article  Google Scholar 

Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2020;173(4):278–86. https://doi.org/10.7326/m20-0864.

Article  PubMed  Google Scholar 

Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23(9):2116–24. https://doi.org/10.1111/dom.14451.

Article  PubMed  CAS  Google Scholar 

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. https://doi.org/10.1097/hep.0000000000000323.

Article  PubMed  PubMed Central  Google Scholar 

Vilar-Gomez E, Vuppalanchi R, Desai AP, Gawrieh S, Ghabril M, Saxena R, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2019;50(3):317–28. https://doi.org/10.1111/apt.15331.

Article  PubMed  CAS  Google Scholar 

Zeng RW, Yong JN, Tan DJH, Fu CE, Lim WH, Xiao J, et al. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment Pharmacol Ther. 2023;57(6):600–9. https://doi.org/10.1111/apt.17371.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol. 2017;23(1):141–50. https://doi.org/10.3748/wjg.v23.i1.141.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol. 2016;65(2):369–76. https://doi.org/10.1016/j.jhep.2016.04.021.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chouik Y, Canivet CM, Julla JB, Mouillot T, Parlati L, Rouland A, et al. Management of patients with type 2 diabetes and MASLD: An overview and joint statement. Diabetes Metab. 2025;51(6):101709. https://doi.org/10.1016/j.diabet.2025.101709.

Article  PubMed  Google Scholar 

Boursier J, Anty R, Carette C, Cariou B, Castera L, Caussy C, et al. Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. Diabetes Metab. 2021;47(5):101272. https://doi.org/10.1016/j.diabet.2021.101272.

Article  PubMed  CAS  Google Scholar 

Colagiuri S, Ceriello A. 7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes. Diabetes Res Clin Pract. 2025;222 Suppl 1:112151. https://doi.org/10.1016/j.diabres.2025.112151

Kinoshita T, Shimoda M, Nakashima K, Fushimi Y, Hirata Y, Tanabe A, et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. J Diabetes Investig. 2020;11(6):1612–22. https://doi.org/10.1111/jdi.13279.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G. Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential. Diabetes Metab Syndr. 2024;18(1):102935. https://doi.org/10.1016/j.dsx.2023.102935.

Article  PubMed  CAS  Google Scholar 

Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, et al. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2019;69(6):2414–26. https://doi.org/10.1002/hep.30320.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised,